Anaerobically stored red blood cells with extended shelf-life
Anaerobically stored red blood cells with extended shelf-life
批准号:
7796811
负责人:
Tatsuro Yoshida
金额:
$98.63万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-06-06 至 2012-03-31
关键词:
Adverse effectsAgeAutologousBloodBlood BanksBlood DonationsBlood TransfusionBlood capillariesCellsCharacteristicsChronicClinicalClinical ResearchClinical TrialsCollectionEquipmentErythrocytesExcisionFrequenciesGasesGoalsHemolysisIn VitroIronJournalsKineticsLeadLifeLogisticsMaintenanceMarketingMedical centerMetabolicMethodsMorphologyOutcomeOxygenPaperPatientsPerformancePerfusionPhasePhysiologicalPostoperative PeriodProceduresProcessRecoveryResearch InfrastructureSickle Cell AnemiaSolutionsSystemTechnologyTestingTimeTissuesToxic effectTransfusionTranslatingUniversitiesbeta Thalassemiacapillarycomparative efficacydesignimprovedin vitro testingnoveloperationprototypepublic health relevance
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The long-term objective of this project is to develop a novel blood storage system that will extend the shelf life of additive system red cell units, and at the same time, deliver red cells of higher efficacy and lower toxicity for transfusion therapy. In this system, red cells are stored in a modified additive solution under oxygen-depleted condition (anaerobic storage). The final product will have extended shelf life (9 weeks or more) as well as higher efficacy and lower toxicity compared to same-aged blood stored by conventional methods (more viable cells, higher oxygen delivery capacity immediately after transfusion and more deformable cells for better capillary perfusion). The new storage system is design to be readily accommodated by the current blood banking operation without incurring major alteration in procedures or equipments. In the Phase I of this project, an experimental procedure was used to demonstrated that anaerobic storage yields; i) a significantly higher post- transfusion recovery compared to the conventional method after 6 weeks of storage; and ii) a comparable 9-week recovery compared to 6-week storage under conventional conditions. The main aim of this Phase II proposal is to demonstrate that an experimental hardware/ processes used in the Phase I can be reduced to practice by fabricating a blood collection/storage system that is self-contained and easily accommodated under current blood bank settings without compromises in its performances. In partnership with University of Pittsburgh, Filtertek and Multisorb Technologies, several prototypes storage system will be designed, fabricated and tested in vitro. Subsequently, an optimized prototype system will be tested in a clinical trial at Dartmouth- Hitchcock Medical Center with a goal of obtaining results comparable to ones attained under experimental procedure in the Phase I. PUBLIC HEALTH RELEVANCE: In the past several years, a number of papers have appeared in scientific journals questioning the quality of red blood cells stored for transfusion. They indicated that; i) worse clinical outcomes were associated with higher number of units transfused; ii) blood transfusion may not have induced increased oxygen utilization in tissues; and iii) worse post-operative outcomes were associated with patients receiving blood stored for longer than 14 days compared with patients receiving less than 14-day old blood. Proposed anaerobic red blood cell storage system delivers higher post- transfusion viability and uncompromised oxygen delivery capacity, thereby improving the efficacy of transfusion therapy while reducing side effects of transfusion. Transfusion of such red cells will reduce the frequency- and time- averaged blood transfusion volume and total iron burden in subjects who require chronic transfusion (e.g., sickle cell disease or beta-thalassemia). Extended shelf life will improve the logistics of general blood bank operations, alleviate the periodic blood shortages, and increase the utility of pre-operative autologous blood donation.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
SBIR Topic 74, Phase I, RBC Storage System to Minimize Storage Lesions
-
批准号:8756926
-
项目类别:
-
资助金额:$19.51万
-
财政年份:2013
-
负责人:Tatsuro Yoshida
-
依托单位:
SBIR Topic 74, Phase I, RBC Storage System to Minimize Storage Lesions
-
批准号:8812757
-
项目类别:
-
资助金额:$146.49万
-
财政年份:2013
-
负责人:Tatsuro Yoshida
-
依托单位:
Anaerobically stored red blood cells with extended shelf-life.
-
批准号:7272589
-
项目类别:
-
资助金额:$13.33万
-
财政年份:2007
-
负责人:Tatsuro Yoshida
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: